Documented allergy to DMSO, mouse or bovine proteins, or iron.
Known allergy or intolerance to any component of belimumab, including human or murine proteins or monoclonal antibodies
History of allergy to mouse proteins
Known allergy to murine proteins or have had a documented anaphylactic reaction to any drug, or a known hypersensitivity to diphenhydramine or other antihistamines of similar chemical structure.
History of allergy to mouse proteins
History of allergy to mouse proteins
Patients who are known to have allergy to mouse proteins
History of allergy to mouse proteins
History of allergy to mouse proteins
History of prior ? grade  hypersensitivity reaction or any toxicity attributed to trastuzumab or murine proteins that warranted permanent cessation of these agents (applicable for Cohort  only).
Allergies or hypersensitivity to murine, chimeric, human or humanised proteins
History of severe environmental allergies or allergy to egg proteins
History of allergy to egg proteins
hypersensitivity to trastuzumab, murine proteins, fulvestrant, or to any of the excipients
History of allergy to murine proteins
History of allergy to murine proteins
History of allergy to mouse proteins
Known hypersensitivity to murine or chimeric antibodies or proteins
History of intolerance (including grade  or  infusion reactions) to murine proteins
History of intolerance, including Grade  to  infusion reaction or hypersensitivity to trastuzumab or murine proteins or any components of the product
Patients with known hypersensitivity to mouse proteins (murine antibodies in ISOLEX) if receiving soybean agglutinin and E-rosetting (SBA-E) bone marrow, or chicken egg products
Patients with known hypersensitivity to mouse proteins (murine antibodies in ISOLEX) if receiving T-cell depleted (soybean lectin agglutination [SBA]-E)- bone marrow, or chicken egg products
History of severe environmental allergies or allergy to egg proteins
No prior history of intolerance or hypersensitivity to trastuzumab and/or adverse events related to trastuzumab, murine proteins, or any of the excipients that resulted in trastuzumab being permanently discontinued
Type I hypersensitivity or anaphylactic reactions to murine proteins or to previous infusion of rituximab
History of intolerance (including grade  or  infusion reaction) or hypersensitivity to trastuzumab or murine proteins
Prior history of hypersensitivity to milk proteins
Patients with a history of allergy to human proteins
Documented allergy to iron dextran or murine proteins
Prior exposure to murine proteins or chimeric antibodies
